摘要
文拉法辛是一种选择性5-羟色胺和去甲肾上腺素重摄取抑制剂,自获批上市以来,在临床广泛用于抑郁症及抑郁症状和抑郁共病的治疗。文拉法辛药理作用机制主要是神经递质和神经可塑性,临床上用于治疗抑郁和抑郁共病,临床不良事件包括药物起效滞后、不良反应和药物相互作用。就文拉法辛与抑郁治疗相关的机制研究及其临床应用和不良事件反馈进行综述。
Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, has been widely used in the clinical treatment of depression, depressive symptoms and depression comorbidities since its approval. The pharmacological mechanism of venlafaxine is mainly neurotransmitter and neuroplasticity. Venlafaxine is used in treatment of depression and depression comorbidities. The clinical adverse events of venlafaxine include delayed drug onset, adverse reactions, and drug interactions. This article reviews the mechanism study, clinical practice, and the adverse events of venlafaxine.
作者
蒋甜鑫
刘晓东
刘李
JIANG Tian-xin;LIU Xiao-dong;LIU Li(Center of Drug Metabolism and Pharmacokinetics,China Pharmaceutical University,Nanjing 211198,China)
出处
《现代药物与临床》
CAS
2021年第1期197-203,共7页
Drugs & Clinic
基金
国家自然科学基金资助项目(82073922,81872930,81673505)
江苏省“333”工程培养资金资助项目(BRA2020287)
中国药科大学“双一流”高校建设项目(CPU2018GY22)。
关键词
文拉法辛
抑郁症
机制
临床应用
不良事件
venlafaxine
depressive disorder
mechanism
clinical practice
adverse event
